J Natl Cancer Inst 2001, 93: 583–596.PubMedCrossRef 25. Hannon GJ: RNA interference. Nature 2002, 418: 244–251.PubMedCrossRef 26. Liu N, Bi F, Pan Y, Sun L, Xue Y, Shi Y, Yao X, Zheng Y, Fan D: Reversal of the Malignant Phenotype of Gastric Cancer Cells by Inhibition of RhoA Expression and Activity. Clinical Cancer Research 2004, 10: 6239–6247.PubMedCrossRef

27. Shimada T, Nishimura Y, Nishiuma T, Rikitake Y, Hirase T, Yokoyama M: Adenoviral Transfer of Rho Family Proteins to Lung Cancer Cells Ameliorates Cell Proliferation and Motility and Increases Apoptotic Change. Kobe J Med Sci 2007, 53: 125–134.PubMed 28. Cheng TL, Teng CF, Tsai WH, Yeh CW, Wu MP, Hsu HC, Hung CF, Chang WT: Multitarget therapy DMXAA in vivo of malignant cancers by the head-to-tail tandem array multiple shRNAs expression system. Cancer Gene Ther 2009, in press. 29. Ren JH, Lin JS, Chang Y, Wu Y, Zhang YH, Zhang Q, He XX: The simultaneous knock-down of Ku70 and Ku80 by a tandem Ku-shRNA-encoding plasmid expression system. Zhonghua Gan Zang Bing Za Zhi 2007, 15: 350–353.PubMed 30. Lei YS, Zhang HZ, Wang LC, Guo LM, Fan QX, Zou CW, Li HX, Wang AB: Construction of vector tandem expressing rat ventricular myocyte Kir2.1 shRNA and its effect in vitro. Zhonghua Yi Xue Za Zhi 2005, 85: 2910–2915.PubMed Competing interests The authors declare

that SRT1720 solubility dmso they have no competing interests. Authors’ contributions LXP, WHB and QS designed the research. LXP and WHB carried out the molecular genetic studies. SAH and SQ participated in the cell culture. YK and SQ discussed the results and analyzed data. LXP and WHB wrote the paper. All authors read and approved the final manuscript.”
“Background We have previously shown that the intrabuccal administration of low and safe levels of electromagnetic fields, amplitude-modulated at a frequency of 42.7 Hz by means of a battery-powered portable device modifies the electroencephalographic

activity of healthy subjects [1, 2], and is associated with subjective and objective relaxation effects [3]. We have also shown that sequential administration of four insomnia-specific frequencies, including 42.7 Hz, results in a significant decrease in sleep latency and a significant increase Thalidomide in total sleep time in patients suffering from AZD1480 in vitro chronic insomnia [4, 5]. This approach has been termed Low Energy Emission Therapy (LEET)[4]. Dosimetric studies have shown that the amount of electromagnetic fields delivered to the brain with this approach is 100 to 1000 times lower than the amount of electromagnetic fields delivered by handheld cellular phones and does not result in any heating effect within the brain [6]. The U.S. FDA has determined that such a device is not a significant risk device. A long-term follow-up survey of 807 patients who have received this therapy in the U.S.